To assess a potential role for RPL22L1 in resistance to 5-FU based therapy, we performed an avatar trial in mice using CRC patient-derived-xenograft (PDX) samples (S1 and S2 Tables). The gene discussed is RPL22L1; the disease is colorectal carcinoma.